{"id":"NCT02980224","sponsor":"OmegaD LLC","briefTitle":"Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease","officialTitle":"A Randomized, Multicenter, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10","primaryCompletion":"2017-02","completion":"2017-02","firstPosted":"2016-12-02","resultsPosted":"2019-09-11","lastUpdate":"2019-12-13"},"enrollment":180,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"OmegaD","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"OmegaD","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase 3 study to evaluate the safety and efficacy of OmegaD softgels for the treatment of dry eye disease. A daily dose of 2 OmegaD softgels dosed orally BID will be compared to 2 placebo softgels dosed orally BID for 84 days. Approximately 164 subjects will be evaluated for their signs and symptoms of dry eye disease and for safety throughout the study.","primaryOutcome":{"measure":"Change From Baseline in Tear Break up Time(TBUT ) at Day 84","timeFrame":"Baseline and 84 Days","effectByArm":[{"arm":"OmegaD","deltaMin":1.45,"sd":0.261},{"arm":"Placebo","deltaMin":1.23,"sd":0.26}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":89},"commonTop":["Upper Respiratory Tract Infection","Diarrhoea","Abdominal discomfort","Abdominal Pain"]}}